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Primary hyperparathyroidism in pregnancy can result in significant maternal and fetal complications. When indicated, prompt
parathyroidectomy in the early second trimester is considered the treatment of choice. Pregnant patients with primary
hyperparathyroidism who have an indication for parathyroidectomy during the first trimester represent a therapeutic challenge.
We present the case of a 32-year-old primigravida who presented with symptomatic hypercalcemia from her primary
hyperparathyroidism. She remained symptomatic despite aggressive conservative management and underwent parathyroidectomy
in her first trimester with excellent outcomes.

1. Introduction
Primary hyperparathyroidism (PHP) is rarely diagnosed
during pregnancy. It is associated with serious maternal
and fetal complications including maternal pancreatitis,
nephrolithiasis, hyperemesis, miscarriage, fetal demise, low
birth weight, neonatal hypocalcaemia, and tetany. Most cases
of PHP during pregnancy are mild, are asymptomatic, and
often go undiagnosed [1]. When diagnosed, PHP associated
with hypercalcemia should be managed promptly. Surgery
(removal of the parathyroid adenoma) in the early second
trimester is considered the treatment of choice in selected
women [2–4]. We present a case of a primigravida with significant symptomatic hypercalcemia who was diagnosed with
PHP and underwent successful parathyroidectomy during
her first trimester of pregnancy.

2. Case Presentation
A 32-year-old primigravida presented to the Emergency
Department (ED) during her 7th week of gestation with complaints of two weeks of progressively worsening intermittent

lower abdominal pain. She denied any visual disturbances,
headache, nausea, vomiting, constipation or diarrhea, vaginal
bleeding, or uterine contractions. Her medical history was
significant for a pituitary microadenoma (6.5 × 6 × 5 mm)
diagnosed 12 months prior. At that time her serum prolactin
was slightly elevated at 35 ng/mL (Ref: 3.34 - 26.72 ng/mL);
however, other pituitary hormones were within the normal
limits. There was no family history of parathyroid disease,
hypercalcemia, nephrolithiasis, or other endocrinopathies
except for hypothyroidism affecting her mother. Admission
medications included daily prenatal vitamins.
On presentation to the ED, her review of systems was otherwise negative with no genitourinary or gastrointestinal or
neurological symptoms. Her vital signs were within normal
limits. Her physical examination was unremarkable.
Her blood tests demonstrated hypercalcemia (serum calcium 12.2 mg/dL [Ref: 8.6-10.3 mg/dL], ionized calcium 1.67
mmol/L [Ref: 1.15 - 1.33 mmol/L]), and hyperparathyroidism
(PTH 135 pg/mL [Ref: 12-88 pg/mL]). Her serum albumin
was 3.2 g/dL (3.5-5.7 g/dL), phosphorus 2.2 mg/dL (Ref: 2.55 mg/dL), and magnesium 1.5 mg/dL (Ref: 1.9-2.7 mg/dL).
Other relevant labs included a 24-hour urinary calcium of 712
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Figure 1: Section of the lesion, showing a diffuse proliferation of cells with loss of the acinar architecture. The lesion show patchy foci of
glandular luminal formation (H&E stain, 100x original magnification).

mg/24 hour (Ref: 100-300 mg/24 hr), 25-hydroxyvitamin D
18.5 ng/mL (Deficient if <20 ng/mL), 1,25-dihydroxyvitamin
D 94.9 pg/mL (Ref: 19.9-79.3 pg/mL), and thyroid stimulating
hormone (TSH) 0.43 uIU/mL (Ref: 0.45-5.33 uIU/mL). Renal
ultrasound was unremarkable with no nephrolithiasis or
hydronephrosis. Thyroid ultrasound revealed a 28 × 11 × 11
mm hypervascular, heterogeneous mass along the posterior
margin of the left thyroid gland. A fine needle aspiration from
the mass demonstrated scant cells and was reported as benign
cytology. The FNA needle washout resulted in high levels of
parathyroid hormone.
She was diagnosed with primary hyperparathyroidism
and started conservative treatment with IV fluid and magnesium supplements with improvement in her serum calcium
levels (11.4 mg/dL). Unfortunately the patient subsequently
became symptomatic with nausea, vomiting, and maintaining serum calcium levels of 12 mg/dL despite sufficient
hydration. She was started on aggressive hydration (lactated
ringers at 125 ml/hr followed by normal saline at 125 ml/hr)
continuously until the day of surgery. She received a total
of 23 L of intravenous fluids over 10 days; however the
serum calcium ranged between 10.6 and 11.6 mg/dL with most
values at >11 mg/dL. Just prior to surgery, her serum calcium
level was 10.7 mg/dL and her ionized calcium level was
1.38 mmol/L. She underwent left superior parathyroidectomy
and the pathology was consistent with a 3.0 × 1.8 × 1.2
cm parathyroid adenoma (Figures 1 and 2). Intraoperative
PTH measurement was not performed to reduce the time of
anesthesia. Following surgery, her serum calcium and PTH
levels normalized. She did not develop hypocalcaemia after
surgery. In subsequent follow-up weekly visits after discharge,
her serum calcium and PTH levels have been within the
normal limits.
With her history of pituitary adenoma and a large
parathyroid adenoma, multiple endocrine neoplasia type
1 (MEN1) was considered. However, direct DNA testing
for MEN1, RET, AIP, and CDKN1B gene mutations were
negative.

3. Discussion
Primary hyperparathyroidism is a common endocrine disorder and has a prevalence estimate of about one to seven

Figure 2: High power view of a representative area, showing that the
lesion is composed of uniform-appearing cells, indicating a single
cell type proliferation, consistent with adenoma (H&E stain, 400x
original magnification).

cases per 1000 adults. The true incidence of PHP is difficult
to estimate; however it is considered to vary between 0.4
and 21.6 cases per 100000 person-years [5]. The incidence
increases with age, and it is two to three times more common
in women [5], with peak incidence in women aged 50-60. The
exact incidence of PHP in pregnancy is unknown, and most
data derives from case reports.
The exact cause of PHP is not known. It was demonstrated
that irradiation to the neck (for benign conditions or in survivors of an atomic bomb) was associated with a significantly
increasing incidence of PHP [6]. MEN 1 and MEN 2 are
examples of genetic mutations associated with PHP [4].
PHP is rarely diagnosed in pregnancy as many cases are
mild and asymptomatic. Moreover, many of the nonspecific
symptoms of pregnancy, such as nausea, vomiting, fatigue,
and constipation, are similar to those associated with hyperparathyroidism, which leads to missed or delayed diagnosis
[2]. It is considered that as many as 80% of cases of PHP
during pregnancy may be asymptomatic. However, untreated
PHP can be associated with significant and serious maternal
(e.g., hypercalcemic crisis, pancreatitis, nephrolithiasis, and
preeclampsia) and fetal (e.g., neonatal tetany, hypoparathyroidism, stillbirth, and miscarriage) complications which
may be as high as 67% and 80% respectively [1, 4]. This may be
an overestimate, taking into account that most cases are mild,
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asymptomatic and undiagnosed, and only clinically evident
cases are likely to be reported [4].
Moreover, a large retrospective study by Abood et al. did
not find any significant difference in pregnancy outcomes
between patients with PHP during pregnancy and agematched controls [7]. Norman et al., however, showed that
hyperparathyroidism in pregnancy had a 3.5 times higher
rate of abortion when compared to the general population.
As expected, the rate of complications increased with the
escalating levels of maternal serum calcium [3].
The diagnosis of PHP during pregnancy is similar to
nonpregnant patients with the exception that physiological
changes in pregnancy (plasma volume expansion) result in
low total serum calcium level; the upper limit of normal
total calcium in pregnancy is considered 9.5 mg/dL [1].
Alternatively, ionized calcium does not change significantly
with pregnancy and may represent a better assay to assess
serum calcium levels during pregnancy [2, 4].
Neck ultrasound is used to identify the parathyroid
adenoma (sensitivity 69%, specificity 94%) as nuclear scans
are contraindicated in pregnancy due to concern for fetal
risk from ionizing radiation [2]. Fine needle aspiration and
needle washout for PTH are not routinely recommended
(it carries a particular risk in patients with parathyroid
cancer). However, since surgery in the first trimester carries
a substantial risk, we wanted to ensure that the nodule
identified in the thyroid ultrasound was indeed a parathyroid
adenoma prior to subjecting the patient to surgery. In the
overall risk calculation, we took into account the facts that
the prevalence of parathyroid carcinoma in the general
population is very low and it usually occurs in the higher
age group. Furthermore, parathyroid carcinoma is associated
with significantly higher serum calcium and PTH levels.
Thus, taking into account the patient’s demographic data, the
clinical presentation and serum calcium, and PTH level, we
considered that her risk of having parathyroid carcinoma was
very low.
In the differential diagnosis, familial hypocalciuric hypercalcemia and hereditary syndromes such as MEN-1 and
MEN-2 should always be considered [2], both of which were
ruled out in our patient.
There are no clear guidelines for management of PHP
during pregnancy. Treatment should be tailored based on
symptoms, severity of hypercalcemia, gestational age, and the
risk-benefit assessment [8].
Mild cases of asymptomatic PHP in pregnancy may
be managed conservatively with a low calcium diet, adequate hydration, and close monitoring of serum calcium. A
small dose of vitamin D may be supplemented cautiously
in deficient patients to decrease PTH levels, as well as
lower the risk of hungry bone syndrome postoperatively if
parathyroidectomy is planned. However, excess and rapid
supplementation can lead to aggravation of the hypercalcemia and hypercalcemic crisis [4]. In more severe cases,
cinacalcet and calcitonin may be used with temporary results.
Bisphosphonates are not indicated in pregnancy because of
the risk of fetal bone toxicity and modeling abnormality [2].
Parathyroidectomy remains the only curative treatment.
In multiple reports, conservative management was shown to
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have higher fetal complications when compared to parathyroidectomy in pregnancy [9, 10]. The current recommendation is to perform parathyroidectomy during the second
trimester of pregnancy due to incomplete organogenesis in
first trimester, and risk of preterm labor in the third trimester
[4]. While there are multiple reports of successful second and
third trimester parathyroidectomy, there are only limited data
on parathyroidectomy during the first trimester. In a review
by Carella et al. [11], parathyroidectomies were reported for all
trimesters with 34/38 live births (7/7 in first trimester, 17/18
in second trimester, 9/12 in third trimester, and 1/1 unspecified). When feasible, a minimally invasive approach rather
than open procedures and intraoperative PTH monitoring
is recommended [2]. Our patient underwent minimally
invasive parathyroidectomy; however, intraoperative PTH
monitoring was not performed in order to reduce time under
anesthesia.
In a retrospective study, Norman et al. [3] reported that
71% of the study participants had prior history of miscarriage
and were able to achieve 100% successful pregnancy outcome
after parathyroidectomy with no subsequent maternal or fetal
complications, demonstrating the efficacy of parathyroidectomy in PHP during pregnancy. Furthermore, the study
emphasized the detrimental effects of increasing maternal
serum calcium levels on pregnancy outcome, with 73%
pregnancy loss when maternal serum calcium levels were 11.4
mg/dL or higher. While pregnancy loss occurred even with
mild elevations in serum calcium at 10.7 mg/dL, fetal death
was more likely to occur when the serum calcium level was
11.4 mg/dL or higher. The study also showed that the majority
of pregnancy loss occurred in the late first or early second
trimester with the majority of pregnancy losses at 10-15 weeks
gestation. Hence, the authors proposed surgical intervention
in the late first or early second trimester rather than waiting
until mid-second trimester, especially with elevated maternal
serum calcium levels of >11.4 mg/dL and prior history of
miscarriage [3]. Our patient underwent parathyroidectomy
in the first trimester, having both symptomatic hypercalcemia
and a serum calcium level >11.4 mg/dL (uncontrollable with
conservative treatment).
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